Abstracts tagged "Cost containment"

Abstract Number: 2277 • 2014 ACR/ARHP Annual Meeting
Inpatient Pediatric Rheumatic Diseases: Characteristics, Cost and Trends
Monica Mahajan¹, Mohammad Shah², Mary Toth^3,4, Neil McNinch⁵ and Moussa El-Hallak⁶, ¹Department of Pediatrics, Akron Children's Hospital, Akron, OH, ²Patient Safety and Quality Services, Akron Children's Hospital, Akron, OH, ³Akron Children's Hospital, Akron, OH, ⁴Rheumatology, Akron Children's Hospital, Akron, OH, ⁵Rebecca D. Considine Research Institute, Akron Children's Hospital, Akron, OH, ⁶Dept of Pediatric Rheumatology, Akron Children's Hospital, Akron, OH
Background/Purpose: Childhood rheumatic diseases (cRD) have wide spectrum of complexity and disease course from mild disease to acute fulminate disease and even sudden death. Physicians…
Abstract Number: 2232 • 2014 ACR/ARHP Annual Meeting
Cost-Effectiveness of Glucosamine, Chondroitin Sulfate, Their Combination, Celecoxib,Non-Selective Non-Steroidal Anti-Inflammatory Drugs, and Placebo in Treating Knee Osteoarthritis
Vishvas Garg¹, Dennis Raisch², Ning Yan Gu³, Matthew E Borrego³ and Daniel O. Clegg⁴, ¹College of Pharmacy, University of New Mexico (at the time of research), Grayslake, IL, ²College of Pharmacy, University of New Mexico, Albuquerque, NM, ³University of New Mexico, Albuquerque, NM, ⁴Rheumatology, George Wahlen VA Medical Center/University of Utah, Salt Lake City, UT
Background/Purpose: Knee osteoarthritis (KOA) affects 13.8% of the US population aged ≥26, causing significant burden-of-illness. We compared the cost-effectiveness of conventional medicines such as non-steroidal…
Abstract Number: 1857 • 2014 ACR/ARHP Annual Meeting
Determinants of Annual Healthcare Utilization and Overall Cost of Care in Individuals with Systemic Lupus Erythematosus in a Large Insurance Claims Database: Glucocorticoid Use
Shih-Yin Chen¹, Chan-Bum Choi^2,3,4, Qian Li⁵, Wei-Shi Yeh¹, Yuan-Chi Lee⁶, Amy H Kao¹ and Matthew H. Liang⁷, ¹Biogen Idec, Cambridge, MA, ²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Section of Rheumatology, VA Healthcare System, Boston, MA, ⁴Department of Aging, Brigham and Women's Hospital, Boston, MA, ⁵Evidera, Lexington, MA, ⁶Formerly of Evidera, Lexington, MA, ⁷Harvard Medical School, Boston, MA
Background/Purpose: Newer therapeutic agents in systemic lupus erythematosus (SLE) may increase cost of care but their effect on limiting the duration and the dosage of…
Abstract Number: 1939 • 2013 ACR/ARHP Annual Meeting
Assessing The Increasing Costs To Manage Patients With Gout By State
Aaron Davis¹ and Jason Wreath², ¹2 calle guijarro, Goutchoices.com, San Clemente, CA, ²Symphony Health, Phoenix, AZ
Background/Purpose: Gout is a chronic progressive disease and worldwide prevalence is increasing. After over 40 years with limited and inexpensive treatments several new and more…
Abstract Number: 1344 • 2013 ACR/ARHP Annual Meeting
Optimal Rheumatoid Arthritis Patient Selection For Biological Treatment From Pharmacoeconomic Perspectives Based On The Institute Of Rheumatology, Rheumatoid Arthritis (IORRA) Cohort
Eiichi Tanaka¹, Eisuke Inoue², Yoko Shimizu³, Akiko Kobayashi², Naoki Sugimoto², Daisuke Hoshi², Kumi Shidara², Eri Sato³, Yohei Seto², Ayako Nakajima⁴, Shigeki Momohara², Atsuo Taniguchi² and Hisashi Yamanaka³, ¹Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: With the recent introduction of biological DMARDs, the economic burden of rheumatoid arthritis (RA) treatment has increased. Previous studies evaluated the cost-effectiveness of biologics,…
Abstract Number: 856 • 2013 ACR/ARHP Annual Meeting
Cost-Effectiveness Of Urate Lowering Strategies For The Management Of Gout
Eric Jutkowitz¹, Karen Kuntz², Laura T Pizzi³ and Hyon Choi^4,5, ¹Divisions of Health Policy and Management (EJ, KMK), School of Public Health, University of Minnesota, Minneapolis, MN, ²Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN, ³Thomas Jefferson University, Philadelphia, PA, ⁴Section of Rheumatology and the Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ⁵Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The new 2012 ACR guidelines for the management of gout have provided updated recommendations; however, the employed method do not address the societal costs…
Abstract Number: 487 • 2013 ACR/ARHP Annual Meeting
The Cost Savings Associated With a Departmental Etanercept Dose Reduction Pathway For Patients With Rheumatic Diseases and Maintained Low Disease Activity
Richard CJ Campbell¹, Emma Sanders¹, Francesca Leone¹, Emma Gilgeours¹, Margaret Sibley¹ and Patrick D. Kiely², ¹Rheumatology, St George's Hospital, London, United Kingdom, ²Rheumatology Dept, St George's Hospital, London, United Kingdom
Background/Purpose: Clinical trials have previously demonstrated that it is safe and effective for some rheumatoid arthritis (RA) patients with low disease activity on full dose…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.